Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Undergraduate School

Pennsylvania State University

1979, University Park, PA

Medical School

Jefferson Medical College

1983, Philadelphia, PA

Internship

Massachusetts General Hospital

1984, Boston, MA

Residency

Massachusetts General Hospital

1987, Boston, MA

Fellowship

Boston Children's Hospital

1989, Boston, MA

Certifications

  • American Board of Allergy & Immunology (Diagnostic Laboratory Immunology)
  • American Board of Allergy & Immunology (General)
  • American Board of Pediatrics (General)

Professional History

Lynda Schneider received her MD from Jefferson Medical College.  She completed an internship and residency at Massachusetts General Hospital and a postdoctoral fellowship at Boston Children’s Hospital.  Dr. Schneider received the 2004 AAAAI/Aventis Women in Allergy Project Grant Award.  In 2009, she served as a member of the NIH Food Allergy Clinical Guideline Expert Panel.  In 2011, she was the Chair on the Atopic Dermatitis Practice Parameter Workgroup.

Publications

  1. Depression and anxiety in patients with atopic dermatitis: Recognizing and addressing mental health burden. Ann Allergy Asthma Immunol. 2025 May; 134(5):506-515. View Abstract

  2. Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study). J Allergy Clin Immunol Pract. 2025 May; 13(5):1190-1200.e3. View Abstract

  3. Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE. J Allergy Clin Immunol Pract. 2025 May; 13(5):1176-1187.e7. View Abstract

  4. Corrigendum to 'A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology' [Annals of Allergy, Asthma & Immunology 133/3 (2024) 286-94]. Ann Allergy Asthma Immunol. 2025 Feb; 134(2):242-243. View Abstract

  5. Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus. Dermatology. 2024; 240(5-6):897-909. View Abstract

  6. Atopic Dermatitis: Updated Guidelines From the AAAAI/ACAAI Joint Task Force on Practice Parameters. Am Fam Physician. 2024 Oct; 110(4):437-439. View Abstract

  7. Updated Guidelines for Atopic Dermatitis-AAAAI/ACAAI Joint Task Force. JAMA Pediatr. 2024 Oct 01; 178(10):961-962. View Abstract

  8. Atopic Dermatitis (Eczema) Guidelines 2023: Highlights. J Allergy Clin Immunol Pract. 2024 Nov; 12(11):2955-2965. View Abstract

  9. Dupilumab treatment reduces caregiver-reported skin pain in patients with moderate-to-severe atopic dermatitis aged 6 months to 5 years. Front Pediatr. 2024; 12:1446779. View Abstract

  10. The Association Between Child Food Allergy and Family Food Insecurity in a Nationally Representative US Sample. Acad Pediatr. 2025 Jan-Feb; 25(1):102565. View Abstract

  11. Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study. Allergy. 2024 Oct; 79(10):2748-2758. View Abstract

  12. Patient-Reported Outcome Measures in Chronic Spontaneous Urticaria, Angioedema, and Atopic Dermatitis. J Allergy Clin Immunol Pract. 2024 Oct; 12(10):2583-2590. View Abstract

  13. Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study. J Allergy Clin Immunol. 2024 Nov; 154(5):1195-1203.e3. View Abstract

  14. Characterization and Incidence of Sunflower Seed Allergy in a Pediatric Allergy Clinic. J Allergy Clin Immunol Pract. 2024 Nov; 12(11):3081-3088.e6. View Abstract

  15. Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus. J Pediatr Clin Pract. 2024 Dec; 14:200121. View Abstract

  16. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2024 Sep; 133(3):286-294. View Abstract

  17. Mental health interventions for atopic dermatitis: knowledge gaps, pilot programmes and future directions. Clin Exp Dermatol. 2023 Dec 19; 49(1):9-17. View Abstract

  18. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024 03; 132(3):274-312. View Abstract

  19. Multi-modal skin atlas identifies a multicellular immune-stromal community associated with altered cornification and specific T cell expansion in atopic dermatitis. bioRxiv. 2023 Oct 31. View Abstract

  20. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023 12; 152(6):1493-1519. View Abstract

  21. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023 12; 152(6):1470-1492. View Abstract

  22. Global warming and implications for epithelial barrier disruption and respiratory and dermatologic allergic diseases. J Allergy Clin Immunol. 2023 11; 152(5):1033-1046. View Abstract

  23. History of S. aureus Skin Infection Significantly Associates with History of Eczema Herpeticum in Patients with Atopic Dermatitis. Dermatol Ther (Heidelb). 2023 Oct; 13(10):2417-2429. View Abstract

  24. Rethinking Immunological Risk: A Retrospective Cohort Study of Severe SARS-Cov-2 Infections in Individuals With Congenital Immunodeficiencies. J Allergy Clin Immunol Pract. 2023 11; 11(11):3391-3399.e3. View Abstract

  25. Rethinking immunologic risk: a retrospective cohort study of severe SARS-CoV-2 infections in individuals with congenital immunodeficiencies. medRxiv. 2023 Jun 05. View Abstract

  26. Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry. J Allergy Clin Immunol Pract. 2023 08; 11(8):2504-2515. View Abstract

  27. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. N Engl J Med. 2023 05 11; 388(19):1755-1766. View Abstract

  28. Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema): A Systematic Review. JAMA Dermatol. 2023 03 01; 159(3):320-330. View Abstract

  29. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023 01; 7(1):13-25. View Abstract

  30. What Parents Should Know About Atopic Dermatitis. JAMA Pediatr. 2022 11 01; 176(11):1156. View Abstract

  31. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2023 01; 151(1):147-158. View Abstract

  32. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022 09 17; 400(10356):908-919. View Abstract

  33. Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2022 10; 10(10):2657-2666.e8. View Abstract

  34. Trustworthy Patient-Centered Guidelines: Insights From Atopic Dermatitis and a Proposal for the Future. J Allergy Clin Immunol Pract. 2022 11; 10(11):2875-2877. View Abstract

  35. Author Correction: DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol. 2022 May; 23(5):815. View Abstract

  36. Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE. Ann Allergy Asthma Immunol. 2022 06; 128(6):660-668.e9. View Abstract

  37. Safely Reducing Hospitalizations for Anaphylaxis in Children Through an Evidence-Based Guideline. Pediatrics. 2022 02 01; 149(2). View Abstract

  38. Atopic Dermatitis and Food Allergy: Best Practices and Knowledge Gaps-A Work Group Report from the AAAAI Allergic Skin Diseases Committee and Leadership Institute Project. J Allergy Clin Immunol Pract. 2022 03; 10(3):697-706. View Abstract

  39. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results. J Allergy Clin Immunol Pract. 2022 07; 10(7):1864-1873.e10. View Abstract

  40. High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy. Cell Rep Med. 2021 10 19; 2(10):100410. View Abstract

  41. Multiethnic genome-wide and HLA association study of total serum IgE level. J Allergy Clin Immunol. 2021 12; 148(6):1589-1595. View Abstract

  42. Anaphylaxis knowledge gaps and future research priorities: A consensus report. J Allergy Clin Immunol. 2022 03; 149(3):999-1009. View Abstract

  43. Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors. J Allergy Clin Immunol. 2022 01; 149(1):145-155. View Abstract

  44. Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum. Allergy. 2021 08; 76(8):2510-2523. View Abstract

  45. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Am J Clin Dermatol. 2021 Mar; 22(2):243-255. View Abstract

  46. Improving patient education for atopic dermatitis: A randomized controlled trial of a caregiver handbook. Pediatr Dermatol. 2021 Mar; 38(2):396-404. View Abstract

  47. Severity grading system for acute allergic reactions: A multidisciplinary Delphi study. J Allergy Clin Immunol. 2021 07; 148(1):173-181. View Abstract

  48. Food allergy and atopic dermatitis. J Food Allergy. 2020 Sep; 2(1):35-38. View Abstract

  49. Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi study. J Allergy Clin Immunol. 2020 11; 146(5):1089-1096. View Abstract

  50. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results. J Allergy Clin Immunol. 2020 10; 146(4):863-874. View Abstract

  51. Nickel Allergic Contact Dermatitis: Identification, Treatment, and Prevention. Pediatrics. 2020 05; 145(5). View Abstract

  52. Combining teledermatology with nonphysician members of the health care team to address access and compliance barriers in pediatric atopic dermatitis: A needs assessment. J Am Acad Dermatol. 2020 Jul; 83(1):237-239. View Abstract

  53. Replicated methylation changes associated with eczema herpeticum and allergic response. Clin Epigenetics. 2019 08 23; 11(1):122. View Abstract

  54. Reply. J Allergy Clin Immunol Pract. 2019 04; 7(4):1376-1377. View Abstract

  55. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. 2019 03 12; 321(10):946-955. View Abstract

  56. Identification of children with anaphylaxis at low risk of receiving acute inpatient therapies. PLoS One. 2019; 14(2):e0211949. View Abstract

  57. Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodies. Ann Allergy Asthma Immunol. 2019 02; 122(2):213-215. View Abstract

  58. Acquired Cold-Induced Urticaria in Pediatric Patients: A 22-Year Experience in a Tertiary Care Center (1996-2017). J Allergy Clin Immunol Pract. 2019 03; 7(3):1024-1031.e3. View Abstract

  59. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab. J Allergy Clin Immunol Pract. 2019 02; 7(2):451-461.e7. View Abstract

  60. A twenty-two-year experience with Hymenoptera venom immunotherapy in a US pediatric tertiary care center 1996-2018. Ann Allergy Asthma Immunol. 2018 12; 121(6):722-728.e1. View Abstract

  61. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018 07; 48(7):825-836. View Abstract

  62. Developing drugs for treatment of atopic dermatitis in children (=3 months to <18 years of age): Draft guidance for industry. Pediatr Dermatol. 2018 May; 35(3):303-322. View Abstract

  63. Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing. PLoS One. 2018; 13(2):e0191987. View Abstract

  64. Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment. J Allergy Clin Immunol Pract. 2018 Sep - Oct; 6(5):1711-1716.e4. View Abstract

  65. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA. 2017 11 14; 318(18):1798-1809. View Abstract

  66. Combining anti-IgE with oral immunotherapy. Pediatr Allergy Immunol. 2017 Nov; 28(7):619-627. View Abstract

  67. Reducing Hospitalization Rates for Children With Anaphylaxis. Pediatrics. 2017 Jun; 139(6). View Abstract

  68. Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Summary of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel. J Acad Nutr Diet. 2017 05; 117(5):788-793. View Abstract

  69. Ditching the Itch with Anti-Type 2 Cytokine Therapies for Atopic Dermatitis. N Engl J Med. 2017 03 02; 376(9):878-879. View Abstract

  70. Addendum guidelines for the prevention of peanut allergy in the United States. JAAPA. 2017 Mar; 30(3):1-5. View Abstract

  71. A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis. J Allergy Clin Immunol. 2017 May; 139(5):1575-1582.e8. View Abstract

  72. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Ann Allergy Asthma Immunol. 2017 02; 118(2):166-173.e7. View Abstract

  73. Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel. J Pediatr Nurs. 2017 Jan - Feb; 32:91-98. View Abstract

  74. Addendum guidelines for the prevention of peanut allergy in the United States: Summary of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Pediatr Dermatol. 2017 Jan; 34(1):5-12. View Abstract

  75. Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel. Pediatr Dermatol. 2017 Jan; 34(1):e1-e21. View Abstract

  76. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. J Allergy Clin Immunol. 2017 Jan; 139(1):29-44. View Abstract

  77. Temporal and Racial Differences Associated with Atopic Dermatitis Staphylococcusaureus and Encoded Virulence Factors. mSphere. 2016 Nov-Dec; 1(6). View Abstract

  78. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017 Mar; 139(3):873-881.e8. View Abstract

  79. Multidisciplinary interventions in the management of atopic dermatitis. J Allergy Clin Immunol. 2016 08; 138(2):325-34. View Abstract

  80. Implementation of a Standardized Clinical Assessment and Management Plan (SCAMP) for Food Challenges. J Allergy Clin Immunol Pract. 2017 Mar - Apr; 5(2):335-344.e3. View Abstract

  81. Study of the Atopic March: Development of Atopic Comorbidities. Pediatr Dermatol. 2016 Jul; 33(4):388-98. View Abstract

  82. Chronic mucocutaneous candidiasis associated with an SH2 domain gain-of-function mutation that enhances STAT1 phosphorylation. J Allergy Clin Immunol. 2016 07; 138(1):297-299. View Abstract

  83. Evaluating a handbook for parents of children with food allergy: a randomized clinical trial. Ann Allergy Asthma Immunol. 2016 Mar; 116(3):230-236.e1. View Abstract

  84. Food Allergy in Infants With Atopic Dermatitis: Limitations of Food-Specific IgE Measurements. Pediatrics. 2015 Dec; 136(6):e1530-8. View Abstract

  85. Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum. J Allergy Clin Immunol. 2015 Dec; 136(6):1591-1600. View Abstract

  86. Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review. Pediatr Allergy Immunol. 2015 Sep; 26(6):537-44. View Abstract

  87. Oral immunotherapy and anti-IgE antibody treatment for food allergy. World Allergy Organ J. 2015; 8(1):20. View Abstract

  88. A Review of Multidisciplinary Interventions in Atopic Dermatitis. J Clin Med. 2015 May 21; 4(5):1156-70. View Abstract

  89. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome associated with neonatal epidermolysis bullosa acquisita. Pediatr Dermatol. 2015 May-Jun; 32(3):e74-7. View Abstract

  90. Ovomucoid specific immunoglobulin E as a predictor of tolerance to cooked egg. Allergy Rhinol (Providence). 2015 Jan; 6(3):198-204. View Abstract

  91. Oral immunotherapy induces IgG antibodies that act through Fc?RIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014 Dec; 134(6):1310-1317.e6. View Abstract

  92. Clinical management of atopic dermatitis: practical highlights and updates from the atopic dermatitis practice parameter 2012. J Allergy Clin Immunol Pract. 2014 Jul-Aug; 2(4):361-9; quiz 370. View Abstract

  93. Flow cytometry biomarkers distinguish DOCK8 deficiency from severe atopic dermatitis. Clin Immunol. 2014 Feb; 150(2):220-4. View Abstract

  94. Eczema and sensitization to common allergens in the United States: a multiethnic, population-based study. Pediatr Dermatol. 2014 Jan-Feb; 31(1):21-6. View Abstract

  95. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013 Dec; 132(6):1368-74. View Abstract

  96. Atopic dermatitis complicated by eczema herpeticum is associated with HLA B7 and reduced interferon-?-producing CD8+ T cells. Br J Dermatol. 2013 Sep; 169(3):700-3. View Abstract

  97. Prenatal food allergen exposures and odds of childhood peanut, tree nut, or sesame seed sensitization. Ann Allergy Asthma Immunol. 2013 Nov; 111(5):391-6. View Abstract

  98. Ovomucoid is not superior to egg white testing in predicting tolerance to baked egg. J Allergy Clin Immunol Pract. 2013 Jul-Aug; 1(4):354-60. View Abstract

  99. A holistic view on dermatitis: patch testing should be considered in patients with atopic dermatitis. Reply. J Allergy Clin Immunol. 2013 Sep; 132(3):772. View Abstract

  100. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013 Feb; 131(2):295-9.e1-27. View Abstract

  101. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2013 Mar; 1(2):142-51. View Abstract

  102. C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies. Pediatr Allergy Immunol. 2013 Feb; 24(1):54-60. View Abstract

  103. Predicting food challenge outcomes for baked milk: role of specific IgE and skin prick testing. Ann Allergy Asthma Immunol. 2012 Nov; 109(5):309-313.e1. View Abstract

  104. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol. 2012 May 13; 13(6):612-20. View Abstract

  105. Role of specific IgE and skin-prick testing in predicting food challenge results to baked egg. Allergy Asthma Proc. 2012 May-Jun; 33(3):275-81. View Abstract

  106. Effect of cat and daycare exposures on the risk of asthma in children with atopic dermatitis. Allergy Asthma Proc. 2012 May-Jun; 33(3):282-8. View Abstract

  107. Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol. 2012 May; 5(3):267-76. View Abstract

  108. Genetic variants in interferon regulatory factor 2 (IRF2) are associated with atopic dermatitis and eczema herpeticum. J Invest Dermatol. 2012 Mar; 132(3 Pt 1):650-7. View Abstract

  109. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study. Allergy. 2011 Dec; 66(12):1604-11. View Abstract

  110. Predictors of clinical success in a multidisciplinary model of atopic dermatitis treatment. Allergy Asthma Proc. 2011 Sep-Oct; 32(5):377-83. View Abstract

  111. Severe atopic dermatitis and transient hypogammaglobulinemia in children. Pediatr Dermatol. 2012 Jan-Feb; 29(1):73-8. View Abstract

  112. The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections. J Allergy Clin Immunol. 2011 Nov; 128(5):1006-14. View Abstract

  113. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol. 2011 Jun; 127(6):1622-4. View Abstract

  114. Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis. J Allergy Clin Immunol. 2011 Jul; 128(1):242-246.e5. View Abstract

  115. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-? response. J Allergy Clin Immunol. 2011 Apr; 127(4):965-73.e1-5. View Abstract

  116. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-Sponsored Expert Panel Report. Nutrition. 2011 Feb; 27(2):253-67. View Abstract

  117. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. Nutr Res. 2011 Jan; 31(1):61-75. View Abstract

  118. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-Sponsored Expert Panel report. J Am Acad Dermatol. 2011 Jan; 64(1):175-92. View Abstract

  119. Research abstracts presented at the Fall Meeting of the New England Society of Allergy, October 23-24, 2010, Woodstock, Vermont. Allergy Asthma Proc. 2011 Jan 01; 32(1):80-81. View Abstract

  120. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011 Mar; 127(3):773-86.e1-7. View Abstract

  121. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol. 2010 12; 126(6):1105-18. View Abstract

  122. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010 Dec; 126(6 Suppl):S1-58. View Abstract

  123. Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls. J Allergy Clin Immunol. 2010 Dec; 126(6):1306-7.e2. View Abstract

  124. Characterizing the relationship between sesame, coconut, and nut allergy in children. Pediatr Allergy Immunol. 2010 Dec; 21(8):1114-8. View Abstract

  125. Tree nut allergy, egg allergy, and asthma in children. Clin Pediatr (Phila). 2011 Feb; 50(2):133-9. View Abstract

  126. Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition. J Allergy Clin Immunol. 2011 Feb; 127(2):524-8. View Abstract

  127. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol. 2010 Nov; 30(6):823-9. View Abstract

  128. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. J Allergy Clin Immunol. 2010 Jun; 125(6):1403-1407.e4. View Abstract

  129. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics. 2010 May; 125(5):e1024-30. View Abstract

  130. Assessment of psychological distress among children and adolescents with food allergy. J Allergy Clin Immunol. 2009 Dec; 124(6):1282-8. View Abstract

  131. Sesame allergy: role of specific IgE and skin-prick testing in predicting food challenge results. Allergy Asthma Proc. 2009 Nov-Dec; 30(6):643-8. View Abstract

  132. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009 Sep; 124(3 Suppl 2):R7-R12. View Abstract

  133. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol. 2009 Sep; 124(3):507-13, 513.e1-7. View Abstract

  134. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009 Aug; 124(2):260-9, 269.e1-7. View Abstract

  135. Sesame Allergy: Role of Specific IgE and Skin Prick Testing in Predicting Food Challenge Results. J Allergy Clin Immunol. 2009 Feb; 123(2 Suppl 1):S24. View Abstract

  136. A girl with severe hand swelling and abdominal cramps. Clin Chem. 2008 Oct; 54(10):1733-6; discussion 1736-7. View Abstract

  137. Evaluation of a group intervention for children with food allergy and their parents. Ann Allergy Asthma Immunol. 2008 Aug; 101(2):160-5. View Abstract

  138. Hypotension from epinephrine in a food-allergic patient with long QT syndrome. Ann Allergy Asthma Immunol. 2008 Feb; 100(2):174-5. View Abstract

  139. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007 Aug; 120(2):416-22. View Abstract

  140. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007 Jul; 120(1):150-5. View Abstract

  141. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet. 2007 Apr; 39(4):430-1. View Abstract

  142. Integrating medical and psychological health care for children with atopic dermatitis. J Pediatr Psychol. 2007 Jun; 32(5):617-25. View Abstract

  143. Assessment of adrenal suppression in children with asthma treated with inhaled corticosteroids: use of dehydroepiandrosterone sulfate as a screening test. Ann Allergy Asthma Immunol. 2006 Aug; 97(2):182-6. View Abstract

  144. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006 Jul; 26(4):388-95. View Abstract

  145. Development of a preliminary questionnaire to assess parental response to children's food allergies. Ann Allergy Asthma Immunol. 2006 Mar; 96(3):472-7. View Abstract

  146. Visceral larva migrans associated with earthworm ingestion: clinical evolution in an adolescent patient. Pediatrics. 2006 Feb; 117(2):e336-9. View Abstract

  147. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005 Aug; 37(8):829-34. View Abstract

  148. Characteristics of mycobacterial infection in patients with immunodeficiency and nuclear factor-kappaB essential modulator mutation, with or without ectodermal dysplasia. J Am Acad Dermatol. 2004 Nov; 51(5):718-22. View Abstract

  149. Clinical features and anaphylaxis in children with cold urticaria. Pediatrics. 2004 Apr; 113(4):e313-7. View Abstract

  150. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol. 2004 Apr; 113(4):725-33. View Abstract

  151. Understanding pediatric inner-city asthma: an explanatory model approach. J Asthma. 2004 Apr; 41(2):167-77. View Abstract

  152. A patient with severe black fly (Simuliidae) hypersensitivity referred for evaluation of suspected immunodeficiency. Ann Allergy Asthma Immunol. 2004 Feb; 92(2):276-80. View Abstract

  153. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003 Jul; 91(1):49-54. View Abstract

  154. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003 Mar 13; 348(11):986-93. View Abstract

  155. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest. 2002 Jun; 109(11):1501-9. View Abstract

  156. Giant cell myocarditis in a 12-year-old girl with common variable immunodeficiency. Mayo Clin Proc. 2002 Jan; 77(1):92-6. View Abstract

  157. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet. 2000 Dec; 67(6):1555-62. View Abstract

  158. X-linked hyper IgM syndrome. Clin Rev Allergy Immunol. 2000 Oct; 19(2):205-15. View Abstract

  159. Atopic diseases and upper respiratory infections. Curr Opin Pediatr. 2000 Oct; 12(5):511-9. View Abstract

  160. Atopic diseases and upper respiratory infections. Curr Opin Pediatr. 1999 Oct; 11(5):475-83. View Abstract

  161. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. J Allergy Clin Immunol. 1999 May; 103(5 Pt 1):810-5. View Abstract

  162. Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Curr Opin Pediatr. 1998 Oct; 10(5):539-47. View Abstract

  163. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immunol. 1998 Jul; 102(1):113-7. View Abstract

  164. Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. Ann Allergy Asthma Immunol. 1998 Mar; 80(3):263-8. View Abstract

  165. Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Curr Opin Pediatr. 1997 Oct; 9(5):537-47. View Abstract

  166. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA. 1996 Nov 20; 276(19):1563-7. View Abstract

  167. Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Curr Opin Pediatr. 1996 Oct; 8(5):531-40. View Abstract

  168. Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics. 1996 Aug; 98(2 Pt 1):211-5. View Abstract

  169. Intravenous immunoglobulin and hepatitis C virus: the Boston episode. Clin Ther. 1996; 18 Suppl B:108-9. View Abstract

  170. Interleukin-4 receptor expression by human B cells: functional analysis with a human interleukin-4 toxin, DAB389IL-4. J Allergy Clin Immunol. 1995 Apr; 95(4):893-900. View Abstract

  171. Quality of care for preschool children with asthma: the role of social factors and practice setting. Pediatrics. 1995 Mar; 95(3):389-94. View Abstract

  172. Treatment of steroid-dependent asthma with recombinant interferon-gamma. Clin Exp Allergy. 1993 Sep; 23(9):785-90. View Abstract

  173. Therapy for patients with recurrent infections and low serum IgG3 levels. J Allergy Clin Immunol. 1993 Aug; 92(2):353-5. View Abstract

  174. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol. 1993 Feb; 28(2 Pt 1):189-97. View Abstract

  175. Lymphokine profile in bone marrow transplant recipients. Blood. 1991 Dec 01; 78(11):3076-80. View Abstract

  176. Induction of germ-line and mature C epsilon transcripts in human B cells stimulated with rIL-4 and EBV. J Immunol. 1990 Nov 15; 145(10):3468-73. View Abstract

  177. Response to a Haemophilus influenzae type b diphtheria CRM197 conjugate vaccine in children with a defect of antibody production to Haemophilus influenzae type b polysaccharide. J Allergy Clin Immunol. 1990 May; 85(5):948-53. View Abstract

  178. Bone marrow transplantation (BMT) for the syndrome of pigmentary dilution and lymphohistiocytosis (Griscelli's syndrome). J Clin Immunol. 1990 May; 10(3):146-53. View Abstract

  179. Regulation of immunoglobulin (Ig)E synthesis in the hyper-IgE syndrome. J Clin Invest. 1990 May; 85(5):1666-71. View Abstract
BESbswy